Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9943348 | The American Journal of Pathology | 2005 | 8 Pages |
Abstract
Tissue inhibitor of metalloproteinases-3 (TIMP-3) is known to inhibit matrix metalloproteinases, aggrecanases, and tumor necrosis factor (TNF)-α-converting enzyme (TACE, ADAM17). These metalloproteases participate in different aspects of joint destruction in inflammatory arthritis. To determine the relative importance of this inhibitor in joint pathology, wild-type and Timp3â/â mice were immunized with methylated bovine serum albumin followed by arthritis induction by intra-articular injection of the same antigen. Animals were monitored for up to 14 days after challenge, and joint tissues were analyzed by routine and Safranin O staining and for the presence of aggrecan neoepitopes produced by metalloprotease cleavage. Serum TNF-α was measured by immunoassay. Compared to wild-type animals, Timp3â/â mice showed a dramatic increase in the initial inflammatory response to intra-articular antigen injection, and serum TNF-α levels were greatly elevated in the Timp3â/â animals after immunization. However, these differences in clinical features disappeared by days 7 to 14. No difference in Safranin O staining or aggrecan cleavage site neoepitope abundance was seen. Thus, in inflammatory joint disease TIMP-3 likely dampens the inflammatory response of TNF-α by reducing ADAM17 activity.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Mandana Mahmoodi, Solmaz Sahebjam, David Smookler, Rama Khokha, John S. Mort,